ArticleFrontiers in medicine2025
Telitacicept administration improved immunoglobulin A nephropathy after hematopoietic stem cell transplantation: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.Frontiers in nutrition · 2026Pooled it
- A retrospective single-center cohort study of major subtypes of primary glomerular diseases (MN, IgAN, and MCD): clinical characteristics, prognostic outcomes, and risk factors.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Telitacicept is a biologic that specifically targets B-lymphocyte stimulator and a proliferation-inducing ligand, demonstrating significant potential for therapeutic applications in B-cell-mediated autoimmune diseases. Currently, telitacicept is primarily utilized in the treatment of systemic lupus erythematosus. However, its therapeutic effect on immunoglobulin A nephropathy (IgAN) after hematopoietic stem cell transplantation (HSCT) has not been reported. This case report presents the clinical outcome of telitacicept administration in the treatment of IgAN following HSCT. Case report: A 36-year-old Asian man developed IgAN following allogeneic HSCT for acute myeloid leukemia (AML). The patient presented with features of high-risk nephrotic syndrome, including a urinary protein quantification of 8.28 g/24 h and serum albumin level of 29 g/L. The patient showed significant clinical improvement following treatment with moderate-dose glucocorticoids combined with telitacicept. After the treatment process, the urine albumin quantification decreased to 0.23 g/24 h, and serum albumin increased to 45.8 g/L. During the treatment, estimated glomerular filtration rate (eGFR) increased from 67.3 to 79.83 mL/min/1.73m Conclusion: This case suggests that telitacicept may be an effective treatment option for IgAN following HSCT, providing valuable insights into future therapeutic strategies for managing post-HSCT IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.